奥沙利铂介入治疗原发性肝癌的临床疗效观察

目的评价以奥沙利铂为主的联合化疗方案介入治疗原发性肝癌的临床疗效及安全性。方法选择2008年1月1日至2009年12月31日在我院接受介入治疗的不可手术切除或术后复发的原发性肝癌患者36例,其中男性31人,女性5人,术中所用化疗方案为奥沙利铂＋羟基喜树碱＋氟脲嘧啶,结合患者肿瘤供血情况选择性行超液态碘化油栓塞,术前术后行血常规、肝肾功能、彩超、肝脏CT平扫检查对比评价治疗效果及安全性。结果共36名患者接受129人次经肝动脉化疗灌注或灌注＋栓塞治疗,PR3例,SD28例,PD5例,临床获益率达86%。平均无进展生存时间7.8个月。结论奥沙利铂是一种安全有效的治疗原发性肝癌的药物。

The clinical effects observation of Oxaliplatin in interventional treatment for primary hepatic carcinoma

【Objective】 To evaluate the effect and safety of interventional therapy with oxaliplatin for liver cance.【Methods】 36 patients with unresectable or recurrent hepatocellular cancer were choosed,that take interventional therapy in our hospital since January 1,2007 to December 31st,2008,including 31 men and 5 women.Oxaliplatin ＋ HCPT ＋ FUDR were used in the treatment,and lipiodol was selected to embolized according to tumor blood supply.The blood routine,liver function,renal function,USG and CT examination of liver were tested before and after treatment and the results were compared for evaluate the effect and safety.【Results】 There are 3 PR,28 SD,5 PD in the 36 patients that were taken the therapy of TAC or TACE for 129 times.Clinical benefit ratio reaches 86%.Median progression-free surial 7.8 months.【Conclusion】 Oxaliplatin is a safe and effective medine for the therapy of primary hepatic carcinoma.